Top Page
Prenetics Group
(NASDAQ:PRE)
Prenetics Group (PRE) vs. SPDR S&P 500 ETF (SPY)
Prenetics Group Business Overview & Revenue Model
Prenetics Group Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 53.26M | 30.62M | 21.74M | 13.16M | 12.53M | 65.18M |
| Gross Profit | 22.48M | 15.40M | 8.83M | 3.62M | 3.60M | 26.34M |
| EBITDA | -57.71M | -51.57M | -47.90M | -218.04M | -209.16M | -1.42M |
| Net Income | -49.81M | -46.30M | -62.72M | -190.45M | -174.01M | -1.94M |
Balance Sheet | ||||||
| Total Assets | 199.11M | 213.57M | 254.17M | 312.13M | 148.51M | 78.88M |
| Cash, Cash Equivalents and Short-Term Investments | 27.71M | 62.81M | 72.74M | 184.12M | 45.19M | 14.80M |
| Total Debt | 2.57M | 5.77M | 2.37M | 6.65M | 491.67M | 17.14M |
| Total Liabilities | 48.21M | 42.23M | 44.01M | 68.67M | 549.40M | 47.88M |
| Stockholders Equity | 150.98M | 170.39M | 206.36M | 237.06M | -400.81M | 31.08M |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | -29.94M | -14.68M | 8.17M | 2.00M | -5.94M |
| Operating Cash Flow | 0.00 | -28.87M | -13.76M | 14.51M | 13.42M | -2.88M |
| Investing Cash Flow | 0.00 | 38.54M | -82.95M | -46.14M | -22.02M | -5.97M |
| Financing Cash Flow | 0.00 | -3.34M | -4.70M | 143.32M | 29.32M | 11.84M |
Prenetics Group Technical Analysis
Prenetics Group Risk Analysis
Prenetics Group Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | $252.44M | -14.97 | -19.87% | ― | 5.44% | 72.17% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $223.29M | -4.34 | -23.93% | ― | 159.45% | 8.59% | |
50 Neutral | $288.20M | -1.96 | -113.23% | ― | -41.87% | -165.76% | |
44 Neutral | $169.78M | -5.67 | -720.01% | ― | 21.68% | 58.30% | |
44 Neutral | $135.60M | -2.18 | -239.53% | ― | 78.62% | 32.39% | |
43 Neutral | $134.85M | ― | -122.81% | ― | 14.08% | 1.34% |
Prenetics Group Corporate Events
On January 1, 2026, Prenetics Global Limited completed the sale of its third-party logistics distribution business operated by subsidiary Europa Sports Partners in an all-stock transaction valued at up to $13 million, as disclosed in a January 6, 2026 filing. The divestiture, which follows the $72 million sale of ACT Genomics in October 2025, is part of an ongoing portfolio optimization that concentrates capital and management attention on IM8, the company’s fastest-growing, highest-margin business line, with management highlighting an expected improvement in operating margins from the second quarter of 2026 as Prenetics exits roughly $6 million in annual operating losses tied to the non-core Europa unit. The transaction leaves fiscal 2025 results unchanged because the sale closed at the start of 2026, while Prenetics maintains a strong liquidity position of more than $70 million in cash and equivalents plus Bitcoin holdings and continues a strategic review of additional non-core assets, including its 35% stake in Insighta, with the stated objective of simplifying its structure and maximizing shareholder returns as IM8 scales globally.
The most recent analyst rating on (PRE) stock is a Hold with a $14.00 price target. To see the full list of analyst forecasts on Prenetics Group stock, see the PRE Stock Forecast page.
On January 5, 2026, Prenetics Global Limited reported that participation in its voluntary warrant exchange program tied to its October 2025 financing round had reached approximately 86.7%, with exchange agreements now covering about 4.72 million of the 5.45 million Class A and Class B warrants originally issued. Those warrants are expected to be exchanged into roughly 2.36 million Class C warrants, cutting the total outstanding warrant count to about 3.08 million—around a 43.3% reduction—and lowering potential dilution on full exercise to about 18.3% of outstanding shares, down from roughly 32.3%. Management indicated that the higher take‑up since its December 23, 2025 update should simplify the company’s capital structure and improve the investability of its ordinary shares; the new Class C warrants carry a lower exercise price, shorter term and a forced-redemption feature, and the exchange was conducted on identical, voluntary terms for all eligible holders.
The most recent analyst rating on (PRE) stock is a Hold with a $14.00 price target. To see the full list of analyst forecasts on Prenetics Group stock, see the PRE Stock Forecast page.
On December 30, 2025, Prenetics Global Limited announced a major capital allocation shift, confirming that it stopped its daily Bitcoin purchases on December 4 and will no longer deploy capital into additional cryptocurrency acquisitions. The company will retain its current holding of 510 Bitcoin as a treasury reserve asset while redirecting all new and existing capital exclusively toward scaling IM8, its high-growth consumer health brand, which has already exceeded $100 million in annualized recurring revenue and is projected to generate $180–$200 million in revenue in fiscal 2026. Backed by a debt-free balance sheet with more than $70 million in cash and cash equivalents, the move consolidates Prenetics’ strategic focus around IM8’s rapid global expansion, product innovation, and brand-building efforts, aiming to enhance long-term shareholder value and sharpen its positioning in the competitive wellness and longevity sector.
The most recent analyst rating on (PRE) stock is a Hold with a $14.00 price target. To see the full list of analyst forecasts on Prenetics Group stock, see the PRE Stock Forecast page.
On December 23, 2025, Prenetics Global Limited announced that it had entered into warrant exchange agreements with holders representing about 83.4% of its outstanding Class A and Class B warrants issued in an October 2025 financing. Under the voluntary program, investors exchanged one Class A and one Class B warrant—previously exercisable at $24.12 and $32.16, respectively, with five-year terms—for a single new Class C warrant exercisable at $18.00 per share for two years once a resale registration statement on Form F-3 becomes effective, and subject to a forced-redemption feature if the stock trades at or above $21.60 for ten consecutive trading days. The transaction, supported by several of Prenetics’ largest institutional shareholders, is expected to swap roughly 4.54 million legacy warrants for about 2.27 million Class C warrants, cutting the total warrant overhang to around 3.18 million instruments—about a 42% reduction from the October issuance, and up to 50% if all holders ultimately participate. Management says the move simplifies the capital structure, materially improves the company’s long-term dilution profile, and enhances the investability of its ordinary shares, while emphasizing that the exchange is not tied to any new financing and that Prenetics has no near-term plans for additional equity or equity-linked capital raising.
The most recent analyst rating on (PRE) stock is a Hold with a $14.00 price target. To see the full list of analyst forecasts on Prenetics Group stock, see the PRE Stock Forecast page.
Prenetics Global Limited, a company involved in the healthcare industry, has announced that it will hold its 2025 annual general meeting of shareholders on December 19, 2025. This meeting will provide an open forum for shareholders to discuss company affairs with management and transact any other business brought before the meeting. The record date for determining shareholders entitled to notice of the meeting is December 11, 2025. This announcement is significant as it allows shareholders to engage directly with the company’s management, potentially impacting future company strategies and decisions.
The most recent analyst rating on (PRE) stock is a Hold with a $14.00 price target. To see the full list of analyst forecasts on Prenetics Group stock, see the PRE Stock Forecast page.
On November 24, 2025, Prenetics Global Limited announced that its executive leadership team purchased approximately $1.45 million worth of the company’s common stock in open market transactions. This move, involving key figures such as CEO Danny Yeung and CFO Stephen Lo, underscores the executives’ confidence in Prenetics’ long-term vision and growth potential. The purchases reflect a strong alignment with shareholders and a belief in the company’s future, particularly as IM8 continues to expand rapidly and the company’s Bitcoin-treasury strategy supports financial resilience.
The most recent analyst rating on (PRE) stock is a Hold with a $11.50 price target. To see the full list of analyst forecasts on Prenetics Group stock, see the PRE Stock Forecast page.
On November 19, 2025, Prenetics Global Limited’s CEO and co-founder, Danny Sheng Wu Yeung, purchased 20,000 shares of the company’s Class A Ordinary Shares at $13.00 each, totaling $260,000. This acquisition increased his total holdings to 96,412 shares, potentially signaling confidence in the company’s future prospects.
The most recent analyst rating on (PRE) stock is a Hold with a $11.50 price target. To see the full list of analyst forecasts on Prenetics Group stock, see the PRE Stock Forecast page.
On November 18, 2025, Prenetics Global Limited’s CEO and co-founder, Danny Sheng Wu Yeung, purchased 20,118 shares of the company’s Class A Ordinary Shares at $12.02 per share, totaling approximately $242,000. This acquisition increases his total holdings to 76,412 shares, reflecting a significant personal investment in the company and potentially signaling confidence in its future performance.
The most recent analyst rating on (PRE) stock is a Hold with a $11.50 price target. To see the full list of analyst forecasts on Prenetics Group stock, see the PRE Stock Forecast page.
On November 14, 2025, Prenetics Global Limited’s Chief Marketing Officer, Rahul Ramchand, purchased 30,000 shares of the company’s Class A Ordinary Shares at $13.29 per share, totaling $398,821. This transaction increased his total holdings to 75,553 shares, reflecting confidence in the company’s market position and potential growth.
The most recent analyst rating on (PRE) stock is a Hold with a $12.50 price target. To see the full list of analyst forecasts on Prenetics Group stock, see the PRE Stock Forecast page.
On November 12, 2025, Prenetics Global Limited’s Chief Marketing Officer, Rahul Ramchand, purchased 30,000 shares of the company’s Class A Ordinary Shares at $13.17 each, totaling $395,151. This acquisition increases his total holdings to 45,553 shares, signaling confidence in the company’s future prospects and potentially impacting investor sentiment positively.
The most recent analyst rating on (PRE) stock is a Hold with a $12.50 price target. To see the full list of analyst forecasts on Prenetics Group stock, see the PRE Stock Forecast page.
On November 10, 2025, Prenetics Global Limited announced its third quarter financial results, showcasing a remarkable 568% year-over-year revenue increase to $23.6 million. The company’s IM8 brand is on track to achieve $120 million in annualized recurring revenue by December 2025, marking the fastest growth in the supplements industry. Prenetics’ financial strength is bolstered by a recent $44 million equity offering, positioning the company for aggressive global expansion. With a strong balance sheet, zero debt, and strategic investments, Prenetics is poised to capitalize on growth opportunities, aiming for a $300 million ARR by the end of 2026.
The most recent analyst rating on (PRE) stock is a Hold with a $12.50 price target. To see the full list of analyst forecasts on Prenetics Group stock, see the PRE Stock Forecast page.
On October 28, 2025, Prenetics Global Limited closed a public offering of 2,722,642 Class A ordinary shares and associated warrants, raising approximately $44 million. The proceeds will be used for the global expansion of IM8 and the development of a Bitcoin treasury strategy. The offering, facilitated by Dominari Securities LLC, reflects Prenetics’ strategic focus on health and digital assets, potentially enhancing its market position and providing growth opportunities.
The most recent analyst rating on (PRE) stock is a Hold with a $13.00 price target. To see the full list of analyst forecasts on Prenetics Group stock, see the PRE Stock Forecast page.
On October 27, 2025, Prenetics Global Limited announced the successful pricing of a public offering, raising approximately $48 million with the potential for $216 million in total proceeds. This strategic capital raise is aimed at fueling the global expansion of its IM8 brand and enhancing its Bitcoin treasury strategy. The offering attracted a distinguished group of investors, including Kraken and American Ventures, highlighting the market’s confidence in Prenetics’ dual-engine growth strategy. The company plans to focus its resources on the IM8 opportunity while strategically accumulating Bitcoin, with a long-term ambition to reach $1 billion in annual revenue and Bitcoin holdings within five years.
The most recent analyst rating on (PRE) stock is a Hold with a $16.50 price target. To see the full list of analyst forecasts on Prenetics Group stock, see the PRE Stock Forecast page.
On October 27, 2025, Prenetics Global Limited announced the successful pricing of a public offering, aiming to raise approximately $48 million. The proceeds are intended to support the global expansion of its IM8 brand and a strategic Bitcoin accumulation plan. This move underscores Prenetics’ innovative approach, combining health sciences with digital asset management, and is expected to enhance its market position and stakeholder value.
The most recent analyst rating on (PRE) stock is a Hold with a $16.50 price target. To see the full list of analyst forecasts on Prenetics Group stock, see the PRE Stock Forecast page.